Valcon Medical

Direct 

• Offering of safe, effective and quality medicines for health-care and human well-being: Valcon Medical manufactures medicinal cannabis products that enhance human well-being, providing alternative treatments for chronic pain, epilepsy, and other conditions where conventional medicines may fail Their products improve symptom management and reduce dependence on addictive opioids.  
  Medical cannabis treats conditions like chronic pain, multiple sclerosis (MS), epilepsy, Spinal cord injury and cancer-related symptoms. It is an option for patients who experience a lack of efficacy or poor tolerance to conventional medicine, and often complements current medication for managing pain, muscle spasms, seizures, and nausea.  
• Promotion of innovation and entrepreneurship: a relevant portion of the funding is dedicated to developing a new product format for the European medical cannabis market – a medical cannabis vaporization and inhalation devices, which provide rapid relief for breakthrough pain. Valcon Medical will invest in advanced extraction technologies to improve the efficiency and yield of cannabis extracts, ensuring that the extracts maintain high potency and purity, crucial for medical applications. By being one of the first to introduce medical cannabis inhalation products in Europe, Valcon Medical positions itself as an industry innovator, setting a benchmark for others and driving industry progress. 
• Creation of jobs: with this funding for the company’s growth, Valcon Medical foresees hiring 10 people during the loan’s two years as permanent positions medical production professionals and regulatory specialists. 

Indirect 

• Implementation of sustainable practices of consumption and production: Valcon Medical, certified by the ISO 14001 for environmental management systems (EMS), implements a strategy for environmental sustainability at the company’s activities level and similar can be found at their supplier. The company uses energy from Danish renewable sources and, in the production, implements efficient extraction technologies that reduce resources consumption and waste. The promoter prioritizes the use of environmentally friendly solvents in extraction processes which are less harmful to the environment and contribute to safer working conditions.  At their primary supplier, Schroll Medical, they implement sustainable agricultural practices: reduced or no synthetic pesticides and fertilizers; efficient water use with efficient techniques like drip irrigation and water recycling in the cultivation; energy efficiency through LED lighting and use of renewable energy from their own solar system; crop rotation and composting; biodegradable and recyclable packaging materials; and prioritization of local suppliers.  
• Promotion of community awareness and advocacy: Valcon Medical is actively involved in policy advocacy to shape effective public policies and access regarding medical cannabis in Denmark and across Europe. Also, the company invests in community outreach programs to educate the public about the benefits and safe use of medical cannabis. 

Valcon Medical A/S, established in 2018 and based in the Greater Copenhagen area of Denmark, is a GMP-licensed pharmaceutical manufacturing organization specializing in the extraction and formulation of medical cannabis.

The positive impact of using medical cannabis on patients is profound, with many finding relief from chronic pain, epilepsy, and other debilitating conditions. Moreover, the adoption of medical cannabis is contributing to a reduction in opioid use, offering a safer alternative for pain management and addressing the opioid crisis that has plagued many regions. This progressive movement marks a significant step forward in healthcare and patient well-being across Europe.

As a leading supplier of medical cannabis extracts in Europe, Valcon Medical is at the forefront of this transformation. The company supplies extracted medical cannabis formulations with therapeutic cannabinoids to pharmaceutical markets across Europe, including Germany, Denmark, the UK, and Poland. In Denmark, Valcon Medical offers a range of products to suit local patient requirements under Valcon’s brand, ScanLeaf. Valcon Medical's product portfolio includes various standardized oil formulations and Germany’s first medical cannabis inhalation product for fast-acting pain relief.

Valcon Medical operates with a clear focus on quality, consistency, and scalability. The company’s management team comprises experienced professionals with backgrounds in pharma, biotech, finance, and regulatory affairs. With a GMP license since 2021 and validated products following European Pharmacopeia standards, Valcon Medical is well-positioned to meet the growing demand for medical cannabis in Europe. The company’s subsidiary, Scanleaf, provides unique access to the Scandinavian market, ensuring direct and efficient distribution of its products.